Get the Stockscreener App
2.91
11.49%
0.30
After Hours:
2.91
Pyxis Oncology Inc stock is traded at $2.91, with a volume of 985.10K.
It is up +11.49% in the last 24 hours and up +5.05% over the past month.
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
See More
Previous Close:
$2.61
Open:
$2.64
24h Volume:
985.10K
Relative Volume:
1.08
Market Cap:
$184.36M
Revenue:
$13.86M
Net Income/Loss:
$-81.74M
P/E Ratio:
-2.2323
EPS:
-1.3036
Net Cash Flow:
$-66.98M
1W Performance:
+29.33%
1M Performance:
+5.05%
6M Performance:
+77.44%
1Y Performance:
+132.80%
1-Day Range:
$2.62
$2.99
1-Week Range:
$2.125
$2.99
52-Week Range:
$0.97
$5.55
Pyxis Oncology Inc Stock (PYXS) Company Profile
Name
Pyxis Oncology Inc
Sector
Industry
Phone
(617) 221-9059
Address
321 HARRISON AVENUE, BOSTON
Compare PYXS vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
2.91 | 165.36M | 13.86M | -81.74M | -66.98M | -1.3036 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-25 | Resumed | Stifel | Buy |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Nov-21-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-08-24 | Initiated | Stephens | Overweight |
| Aug-08-24 | Initiated | Stifel | Buy |
| May-07-24 | Resumed | Jefferies | Buy |
| Feb-09-24 | Initiated | BTIG Research | Buy |
| Jan-23-24 | Initiated | Leerink Partners | Outperform |
| Sep-05-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-02-21 | Initiated | BofA Securities | Neutral |
| Nov-02-21 | Initiated | Credit Suisse | Outperform |
| Nov-02-21 | Initiated | Jefferies | Buy |
View All
Pyxis Oncology Inc Stock (PYXS) Latest News
Pyxis Oncology Inc (PYXS) Balance Sheet - TradingKey
Pyxis Oncology Inc (PYXS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pyxis Oncology Inc (PYXS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pyxis Oncology Inc (PYXS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PYXS|Pyxis Oncology Inc|Price:2.610|Chg%:-0.070 - TradingKey
Pyxis Oncology Inc (PYXS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Pyxis Oncology Inc (PYXS) Institutional Confidence - TradingKey
PYXS|Pyxis Oncology Inc|Price:2.600|Chg%:-0.080 - TradingKey
Pyxis Oncology Inc (PYXS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pyxis Oncology Inc (PYXS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pyxis Oncology Inc (PYXS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PYXS stock trades steady as Pyxis Oncology highlights cash runway and clinical progress - Ad-hoc-news.de
Craig D Gordon Net Worth (2026) - GuruFocus
BIOTECHNOLOGY VALUE FUND L P's Strategic Acquisition in Pyxis Oncology Inc. - GuruFocus
Pyxis Oncology: The Market Might Have Already Ruled On Micvotabart Pelidotin - Seeking Alpha
Pyxis Oncology (PYXS) Declines 7.87% as Stock Tests Key Support Near $2.34Percent Above MA - dars.gov.et
Pyxis Oncology (PYXS) Declines Over 7%, Trading Near Critical Support LevelPassive Flow - dars.gov.et
Pyxis Oncology (NASDAQ: PYXS) sees GordonMD entities report over 10M shares and large warrant stake - Stock Titan
Biotechnology Value Fund group (NASDAQ: PYXS) reports 9.99% capped stake in Pyxis - Stock Titan
Pyxis Oncology Inc (NASDAQ: PYXS) Share Price, PYXS Stock News, PYXS Share Price & Updates - Kalkine
RBC Capital Reaffirms Their Buy Rating on Pyxis Oncology (PYXS) - The Globe and Mail
RBC Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Pyxis Oncology Company Profile & Introduction - Moomoo
PYXIS ONCOLOGY INC (PYXS) Stock Price & Overview - ChartMill
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS) and Glaukos (GKOS) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS) and Nektar Therapeutics (NKTR) - The Globe and Mail
H.C. Wainwright reiterates Pyxis Oncology stock rating at buy - Investing.com UK
H.C. Wainwright reiterates Pyxis Oncology stock rating at buy By Investing.com - Investing.com Nigeria
H.C. Wainwright Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Pyxis Oncology(PYXS) Stock Options Chain | Quotes & News - Moomoo
PYXS Maintains by Leerink Partners -- Price Target Lowered to $7 - GuruFocus
Pyxis Oncology Raises Capital Through Private Placement Financing - TipRanks
Pyxis Oncology (PYXS) director sells 35K shares after option exercise - Stock Titan
Pyxis Oncology Raises $50 Million in Private Placement; Warrants Could Add ~$64 Million - TradingView
Pyxis Oncology (NASDAQ: PYXS) raises up to $114M in private placement to fund MICVO trials - Stock Titan
GordonMD entities report 10,024,909 PYXS shares (PYXS) - Stock Titan
Leerink cuts Pyxis Oncology stock price target on valuation - Investing.com
Leerink cuts Pyxis Oncology stock price target on valuation By Investing.com - Investing.com India
Pyxis Oncology, Inc. Financial Disclosures & SEC Filings - TradingView
Pyxis Oncology Secures $114M for MICVO Cancer Trial - AllSci
Pyxis Oncology, Inc. Stock 12‑Month Price Target Raised to $7.14, Implies 137% Upside - TradingView
Latham & Watkins Advises on Pyxis Oncology’s Up to US$114 Million Private Placement Financing - Legal Desire Media and Insights
William Blair Maintains Pyxis Oncology(PYXS.US) With Hold Rating - Moomoo
Form 144 Pyxis Oncology For: 30 June By Investing.com - Investing.com Australia
[144] Pyxis Oncology, Inc. SEC Filing - Stock Titan
Pyxis Oncology, Inc. (PYXS) announced the completion of a private financing agreement with a total funding amount up to 114 millions dollars. - Bitget
Pyxis OncologyExpects Updated Phase 1 Mono - Moomoo
Pyxis Oncology Announces up to $114 Million P - Moomoo
Pyxis Oncology Secures Up to $114 Million Private Placement - marketscreener.com
Pyxis Oncology (PYXS) Secures $50 Million in Private Placement F - GuruFocus
Pyxis Oncology Announces Up To $114 Million Private Placement Financing To Advance Micvo Through Key Clinical Milestones - TradingView
Pyxis Oncology Inc Stock (PYXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):